OncoJan TM: CD95 targeted formulation of paclitaxel for treatment of ovarian cancer
Lead Research Organisation:
Queen Mary University of London
Department Name: Blizard Institute of Cell and Molecular
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Publications
Ateh DD
(2011)
The intracellular uptake of CD95 modified paclitaxel-loaded poly(lactic-co-glycolic acid) microparticles.
in Biomaterials
| Description | We discovered that we can use the same dose of a standard chemotherapy drug used in ovarian cancer and package it up so that it is 65 times more effective, with lower side effects. |
| Exploitation Route | In the development of human therapies |
| Sectors | Healthcare |
| Description | Employment in an area of deprived community. Development of UK industry and economic development. |
| First Year Of Impact | 2007 |
| Sector | Healthcare |
| Impact Types | Societal Economic |
| Description | Horizon 2020 |
| Amount | £638,000 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 09/2020 |
| Description | Translational neuroscience student session |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Study participants or study members |
| Results and Impact | Groups of students were introduced into drug development and SME creation using the real life examples from the project and Biomoti formation. |
| Year(s) Of Engagement Activity | 2013,2014,2015,2016 |